Table 1.
Breast cancer trial cost-utility analysis.
|
|
Intervention group (n=74) | Control group (n=75) |
|
|
|
||||||
|
|
Mean (SD) | Mean (SD) | P value | t test (df)a | 95% CI | ||||||
| Health utility |
|
|
|
|
|
||||||
|
|
QALYsb,c | –0.004 (0.002) | –0.012 (0.002) | <.001 | 80 (1998) | 0.0074-0.0078 | |||||
|
|
Incremental QALYsb | 0.0076 (0.003) | N/Ad | N/A | N/A | N/A | |||||
| Costs (€e) |
|
|
|
|
|
||||||
|
|
Intervention costs | 92 (2) | N/A | N/A | N/A | N/A | |||||
| All health care costs (€) |
|
|
|
|
|
||||||
|
|
Outpatient | 27,571 (6392) | 26,348 (5800) | N/A | N/A | N/A | |||||
|
|
Inpatient | 9207 (5254) | 9093 (5460) | N/A | N/A | N/A | |||||
|
|
Total | 36,882 (1032) | 35,427 (959) | <.001 | 33 (1987) | 33,530-37,351 | |||||
|
|
Incrementalb | 1454 (1386) | N/A | N/A | N/A | N/A | |||||
| Acute health care costs (€) |
|
|
|
|
|
||||||
|
|
Outpatient | 554 (597) | 562 (606) | N/A | N/A | N/A | |||||
|
|
Inpatient | 2932 (4023) | 2665 (3992) | N/A | N/A | N/A | |||||
|
|
Total | 3585 (480) | 3235 (494) | <.001 | 16 (1998) | 2242-4214 | |||||
|
|
Incrementalb | 353 (676) | N/A | N/A | N/A | N/A | |||||
| ICERab,f | 202,368 (811,136) | N/A | N/A | N/A | 152,008-252,728 | ||||||
| ICERbb | 49,903 (207,042) | N/A | N/A | N/A | 37,049-62,758 | ||||||
| ICERcb | 13,213 (33,327) | N/A | N/A | N/A | 11,145-15,281 | ||||||
aIndependent unpaired samples Student t test (2-tailed).
bBased on bootstrap.
cQALY: quality-adjusted life year.
dN/A: not applicable.
e€1=US $1.03.
fICER: incremental cost-effectiveness ratio.